Analysis and Validation of Key Genes Related to Radiosensitivity in Prostate Cancer
Purpose: To investigate the potential relationship between differential gene expression, biological function enrichment and disease prognosis affecting the sensitivity of prostate cancer radiotherapy by bioinformatics analysis.
Materials and Methods: Retrieve and obtain data on differential gene expression of prostate cancer radiosensitivity in the GEO database (GSM3954350, GSM3954351, GSM3954352), GER2 tool to screen and analyze the differential genes, Enrichr database for enrichment analysis of GO and KEGG, use Cytoscape software builds protein-protein interaction (PPI) networks and analyzes key genes.
Results: A total of 7043 differentially expressed genes were screenedout, including 3842 high expression genes and 3199 low expressed genes. The top 20 differentially expressed genes were selected for further analysis. Their biological functions are mainly enriched in the following aspects:“Cell communication” and “Signal transduction”; cytological components are mainlylocated outside the cell; molecular functions are enriched in structural molecular activity, receptor binding, serine-like peptidase activity, etc. The KEGG enrichmentanalysisshowedthat the differentially expressed genes were mainly enriched in the mismatch repair pathway, non-homologous terminal binding pathway and so on.Survival analysis showed that VGF gene was associated with the prognosis of prostate cancer patients receiving radiotherapy, and high expression of VGF significantly reduced progression-free survival(PFS) in these patients(HR=4.84, 95% CI: 1.34-17.5, P= .016).
Conclusion:This study identified key genes associated with radiation sensitivity in prostate cancer and verified the relationship between the VGF gene and patient prognosis
- Prostate cancer; radiotherapy sensitivity; bioinformatics
How to Cite
2. Mottet N, van den Bergh R C N, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Eur Assoc Urol, 2019, 75(6): 889-90.
3. Bolla M , De Reijke T M , Van Tienhoven G , et al. DURATON OF ANDROGEN SUPRESSON N THE TREATMENT OF PROSTATE CANCER. New England Journal of Medicine, 2009, 360(24):2516.
4. Thompson IM, Tangen CM, Paradelo J. Adjuvant radiotherapy for pathological
T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term follow-up of a randomized clinical trial. J Urol, 2009, 181:956-962.
5. Polkinghorn W R , Zelefsky M J . Improving outcomes in high-risk prostate cancer with radiotherapy. Reports of Practical Oncology & Radiotherapy Journal of Greatpoland Cancer Center in Poznań& Polish Society of Radiation Oncology, 2013, 18(6):333-337.
6. Chang L , Graham P , Hao J , et al. Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy. Cancer & Metastasis Reviews, 2014, 33(2-3):469-496.
7.Chang Lei,Graham Peter H,HaoJingli et al. Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.Cancer Metastasis Rev., 2014, 33: 469-96.
8.Russo G , Zegar C , Giordano A . Advantages and limitations of microarray technology in human cancer. Oncogene, 2003, 22(42):6497-6507.
9. Szklarczyk Damian, Franceschini Andrea, Kuhn Michael et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nuclc Acids Research, 2010, 39(Database issue):D561-8.
10. Johansson Silvia,AströmLennart,Sandin Fredrik et al. Hypofractionated proton boost combined with external beam radiotherapy for treatment of localized prostate cancer.Prostate Cancer, 2012, 2012: 654861.
11. PahlajaniNiraj,Ruth Karen J,Buyyounouski Mark K et al. Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer.Int. J. Radiat. Oncol. Biol. Phys., 2012, 82: 1949-56.
12. Barker Holly E,Paget James T E,KhanAadil A et al. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence.Nat. Rev. Cancer, 2015, 15: 409-25.
13. Chang Lei,Graham Peter H,HaoJingli et al. Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.Cancer Metastasis Rev., 2014, 33: 469-96.
14. Seifert M, Peitzsch C, Gorodetska I, et al. Network-based analysis of prostate cancer cell lines reveals novel marker gene candidates associated with radioresistance and patient relapse. PLoS computational biology, 2019, 15(11): e1007460.
15.Bonkhoff H . Factors Implicated in Radiation Therapy Failure and Radiosensitization of Prostate Cancer. Australasian Radiology, 2012, 2012(6):584.
16. Chaiswing L , Weiss H L , Jayswal R D , et al. Profiles of Radioresistance Mechanisms in Prostate Cancer. Critical reviews in oncogenesis, 2018, 23(1-2):39.
17. Marwitz S , Heinbockel L , Scheufele S , et al. Epigenetic modifications of the VGF gene in human non-small cell lung cancer tissues pave the way towards enhanced expression. Clinical Epigenetics, 2017, 9(1):123.
18. Wang Xiuxing,Prager Briana C,WuQiulian et al. Reciprocal Signaling between Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression.Cell Stem Cell, 2018, 22: 514-528.e5.
- Abstract Viewed: 0 times
- Just Accepted/6967 Downloaded: 0 times